Keyword Connections

myelofibrosis

Journals

7

1 Blood

2 British journal of haematology

3 Annals of hematology

4 international journal of hematology

5 blood cancer journal

6 clinical advances in hematology & oncology : h&o

7 cancer treatment and research

Research Groups

0

No Research Group Connected

Bibliographies

37

1 Mutational profiling in myelofibrosis: implications for management.

2 Myelofibrosis in 2019: moving beyond JAK2 inhibition.

3 A journey through infectious risk associated with ruxolitinib.

4 Management of advanced phase myeloproliferative neoplasms.

5 Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

6 Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.

7 How I treat polycythemia vera.

8 Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.

9 t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma.

10 Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.

11 Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

12 Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.

13 Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.

14 Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management

15 Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

16 Recent advances in the diagnosis and management of primary myelofibrosis

17 Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement

18 Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management

19 Zoledronic acid administration is effective for hematopoiesis management in a patient with primary myelofibrosis

20 Actualities in the management of primary myelofibrosis

21 Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors

22 Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT/ELN international working group

23 Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

24 Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management

25 Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis

26 Erratum to Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

27 Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

28 Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management

29 Advances in the understanding and management of primary myelofibrosis

30 Diagnostic and therapeutic progress in the management of primary myelofibrosis

31 Management of myelofibrosis during pregnancy: A case report

32 Treatment and management of myelofibrosis in the era of JAK inhibitors

33 ruxolitinib treatment in a patient with primary myelofibrosis resistant to conventional therapies and splenectomy: a case report

34 generation and characterization of a human induced pluripotent stem (ips) cell line derived from an acute myeloid leukemia patient evolving from primary myelofibrosis carrying the calr 52 bp deletion and the asxl1 p.r693x mutation

35 acute panmyelosis with myelofibrosis - a rare subtype of acute myeloid leukemia

36 ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the budd-chiari syndrome.

37 MYELOFIBROSIS IN CHILDREN: Experience at a Single Tertiary Care Center in India